"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity." ...

Additionally, the U.S. FDA has approved new treatments spanning various conditions, from cystic fibrosis to obstructive sleep ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The FDA has granted approval for its first medication for certain patients with sleep apnea—the weight-loss drug Zepbound.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Makary will “restore FDA to the Gold Standard of Scientific Research, and cut the bureaucratic red tape at the Agency to make sure Americans get the Medical Cures and Treatments they deserve ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept. 23 in Children. In a new analysis of national data, researchers at the ...

Obstructive sleep apnea (OSA) and the metabolic syndrome have a strong association with each other owing to their common feature of obesity, but an association independent of obesity has been ...

Lilly submitted data for tirzepatide in moderate-to-severe obstructive sleep apnea (OSA) and obesity and heart failure with preserved ejection fraction (HFpEF) and obesity to the US FDA and other ...

Tirzepatide is in a class of its own as the only FDA-approved dual GIP and GLP ... an additional related health issue such as obstructive sleep apnea or heart disease. None of the trial subjects ...